The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
European patents granted for the Netherlands in which a translation was filed ex Article 52 par. 1 of the NL Patent Law 1995
4
Bulletin Heading:
EP2
Journal edition number:
2010/02
Publication date:
01/02/2010
Description:
European patents granted for the Netherlands
European Patent Bulletin
Issue number:
200950
Publication date:
09/12/2009
Description:
Grant (B1)
Deed
Licence
Change Kind/ Decision Type:
Licence termination
Deed Number:
020996-A020996-1
Date Registered:
26/11/2013
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
ir. M.F.J.M. Ketelaars c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:
Changed Pledgee
Name:
Address:
Removed Usufructuary
Name:
Address:
Added Usufructuary
Name:
Address:
Changed Usufructuary
Name:
Address:
Licence
Change Kind/ Decision Type:
New licence registration
Deed Number:
LRFC-502A
Date Registered:
04/01/2013
License Effective Date:
12/04/2012
License Expiration Date:
26/11/2013
Scope of License:
Not Exclusive
Journal Edition Number:
Text:
Beeindiging Licentie door NLO. Zie verder de akte. Expired
Deed Status:
Country Code:
Netherlands (NL)
Updated License Number:
Terminated License Number:
Added Licensee(s)
Name:
AstraZeneca AB
Address:
Västra Mälarehamnen 9, SE-151-85, Södertälje, Sweden (SE)
Changed Pledgee
Name:
Address:
Removed Usufructuary
Name:
Address:
Added Usufructuary
Name:
Address:
Changed Usufructuary
Name:
Address:
Licence
Change Kind/ Decision Type:
New licence registration
Deed Number:
019020-A019020-1
Date Registered:
04/01/2013
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
ir. M.F.J.M. Ketelaars c.s.
Journal Edition Number:
Text:
Exclusieve licentie ingediend op 4 januari 2013 door Nederlands Octrooibureau te Den Haag. Licentiegever is Rigel Pharmaceuticals, Inc te San Fransisco, Verenigd Staten van Amerika. Zie verder akte.